se ha leído el artículo
array:24 [ "pii" => "S1578219014001127" "issn" => "15782190" "doi" => "10.1016/j.adengl.2014.04.006" "estado" => "S300" "fechaPublicacion" => "2014-06-01" "aid" => "826" "copyright" => "Elsevier España, S.L. and AEDV" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2014;105:469-82" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3981 "formatos" => array:3 [ "EPUB" => 41 "HTML" => 3232 "PDF" => 708 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731013001099" "issn" => "00017310" "doi" => "10.1016/j.ad.2012.12.019" "estado" => "S300" "fechaPublicacion" => "2014-06-01" "aid" => "826" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2014;105:469-82" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 25454 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 18142 "PDF" => 7310 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Actualización en el tratamiento de la urticaria crónica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "469" "paginaFinal" => "482" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Update on the Treatment of Chronic Urticaria" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2333 "Ancho" => 2250 "Tamanyo" => 269838 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algoritmo de tratamiento de la urticaria crónica espontánea según la «BSACI guidelines for the management of chronic urticaria and angio-oedema» de 2007. Reproducida con el permiso de los «Standards of Care Committee British Society for Allergy and Clinical Immunology».</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Curto-Barredo, J.F. Silvestre, A.M. Giménez-Arnau" "autores" => array:3 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Curto-Barredo" ] 1 => array:2 [ "nombre" => "J.F." "apellidos" => "Silvestre" ] 2 => array:2 [ "nombre" => "A.M." "apellidos" => "Giménez-Arnau" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219014001127" "doi" => "10.1016/j.adengl.2014.04.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014001127?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013001099?idApp=UINPBA000044" "url" => "/00017310/0000010500000005/v1_201405270041/S0001731013001099/v1_201405270041/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219014001255" "issn" => "15782190" "doi" => "10.1016/j.adengl.2014.04.019" "estado" => "S300" "fechaPublicacion" => "2014-06-01" "aid" => "10000" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2014;105:483-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1669 "formatos" => array:3 [ "EPUB" => 42 "HTML" => 1253 "PDF" => 374 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Controversies in Dermatology</span>" "titulo" => "Biologic Therapies for Moderate to Severe Psoriasis Are Not Interchangeable" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "483" "paginaFinal" => "486" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Los tratamientos biológicos de la psoriasis moderada a grave no son alternativas terapéuticas equivalentes" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 837 "Ancho" => 1670 "Tamanyo" => 49129 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Assessment and positioning of 2 drugs as clinically equivalent therapeutic alternatives. In cases A and B, the 2 drugs can be considered to be clinically equivalent therapeutic alternatives even if treatment failure would imply serious or irreversible harm to the patient. In the doubtful or inconclusive cases (C-E) the 2 drugs cannot be considered to be equivalent therapeutic alternatives if failure would imply serious or irreversible harm to the patient, but they could conditionally be accepted as equivalent if this were not the case. F and G, for which the difference in risk difference exceeds the predefined delta value, can never be considered to be clinically equivalent therapeutic alternatives.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Puig" "autores" => array:1 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Puig" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731013002834" "doi" => "10.1016/j.ad.2013.08.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013002834?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014001255?idApp=UINPBA000044" "url" => "/15782190/0000010500000005/v1_201405281018/S1578219014001255/v1_201405281018/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219014001231" "issn" => "15782190" "doi" => "10.1016/j.adengl.2014.04.017" "estado" => "S300" "fechaPublicacion" => "2014-06-01" "aid" => "802" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2014;105:459-68" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2388 "formatos" => array:3 [ "EPUB" => 45 "HTML" => 1934 "PDF" => 409 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Evaluating Clinical Dermatology Practice in Medical Undergraduates" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "459" "paginaFinal" => "468" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evaluación de las prácticas clínicas de Dermatología en el grado de Medicina" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 878 "Ancho" => 1788 "Tamanyo" => 122319 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Miller's pyramid of learning, adapted from Fornells-Vallés.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> The mini-CEX is the mini-clinical evaluation exercise; OSCE refers to objective structured clinical evaluation; WPBA, workplace-based assessment.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.M. Casanova, V. Sanmartín, R.M. Martí, J.L. Morales, J. Soler, F. Purroy, R. Pujol" "autores" => array:7 [ 0 => array:2 [ "nombre" => "J.M." "apellidos" => "Casanova" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Sanmartín" ] 2 => array:2 [ "nombre" => "R.M." "apellidos" => "Martí" ] 3 => array:2 [ "nombre" => "J.L." "apellidos" => "Morales" ] 4 => array:2 [ "nombre" => "J." "apellidos" => "Soler" ] 5 => array:2 [ "nombre" => "F." "apellidos" => "Purroy" ] 6 => array:2 [ "nombre" => "R." "apellidos" => "Pujol" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731013000379" "doi" => "10.1016/j.ad.2012.12.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013000379?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014001231?idApp=UINPBA000044" "url" => "/15782190/0000010500000005/v1_201405281018/S1578219014001231/v1_201405281018/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Update on the Treatment of Chronic Urticaria" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "469" "paginaFinal" => "482" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "L. Curto-Barredo, J.F. Silvestre, A.M. Giménez-Arnau" "autores" => array:3 [ 0 => array:4 [ "nombre" => "L." "apellidos" => "Curto-Barredo" "email" => array:1 [ 0 => "laia.curto@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J.F." "apellidos" => "Silvestre" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "A.M." "apellidos" => "Giménez-Arnau" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital del Mar-Parc de Salut Mar, Universitat Autónoma, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital General universitario, Alicante, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Actualización en el tratamiento de la urticaria crónica" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 4333 "Ancho" => 2833 "Tamanyo" => 714773 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Algorithm for the management of patients with chronic spontaneous urticaria. Source: Maurer et al.,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> with the permission of the authors.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">QoL indicates quality of life; nsAH, nonsedating antihistamine.</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Based on the algorithm for the management of patients with chronic spontaneous urticaria. Source: Maurer et al.,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> with permission.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Etiological and Pathophysiological Aspects to Be Taken Into Account in the Treatment of Chronic Urticaria</span><p id="par0005" class="elsevierStylePara elsevierViewall">A large number of factors can trigger the onset of urticaria and/or angioedema, including physical stimuli (cold, heat, pressure, vibration, UV light), drugs (nonsteroidal anti-inflammatory drugs [NSAIDs], angiotensin-converting enzyme inhibitors, opioids), infections (<span class="elsevierStyleItalic">Helicobacter pylori</span>, intestinal parasites), foods, hypocomplementemia, and autoimmune disorders. To date, in contrast to urticarial vasculitis, no relationship has been detected between urticaria and malignancy. Due to the lack of consensus on the definition of the causative criteria, notable differences exist between authors regarding identification of the etiological factors implicated in chronic spontaneous urticaria. In some series, an etiological factor is identified in up to 40% to 50% of cases. The traditional term <span class="elsevierStyleItalic">chronic idiopathic urticaria</span> should be avoided or reserved only for those cases in which no etiological factor can be identified.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The main effector cell in the production of the wheal is the cutaneous mast cell, which, after its activation, undergoes degranulation with the release of histamine and other vasoactive and proinflammatory mediators. Potential mast-cell activators include opioids, immunoglobulin (Ig) <span class="elsevierStyleHsp" style=""></span>E (mast cells have a high-affinity IgE receptor [FC¿RI] on their cell membranes), complement factors (C5A), and substance<span class="elsevierStyleHsp" style=""></span>P. Once activated, mast cells release granules that mainly contain histamine, though other inflammatory mediators are also present, such as platelet activating factor (PAF), tumor necrosis factor (TNF), interleukin (IL) 3, IL-4, IL-5, IL-6, IL-8, IL-13, granulocyte-macrophage colony stimulating factor (GM-CSF), prostaglandin (PG) D-2, and leukotrienes (LT) (LTC4, LTD4, LTEA). Histamine, TNF, and IL-8 also stimulate endothelial adhesion molecules, which favor eosinophil, monocyte, and neutrophil migration from the bloodstream into the skin.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a> It has recently been suggested that thrombin could play a role in the pathogenesis of chronic urticaria (CU), as this molecule has been found to increase vascular permeability, to act on the complement pathway, and to promote mast-cell degranulation.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The chronic form of urticaria (wheals and/or angioedema lasting more than 6 weeks) is a skin disease with a prevalence in the general population between 0.1% and 3%.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> Many patients with CU report a considerable reduction in quality of life as a result of the pruritus, sleep disturbances, fatigue, social isolation, and emotional disorders; its impact on quality of life is comparable to that suffered by patients with severe coronary artery disease.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,9</span></a> Chronic spontaneous urticaria accounts for around 70% of all cases of CU and can persist for several years.</p><p id="par0020" class="elsevierStylePara elsevierViewall">It has been shown that approximately a third of patients with chronic spontaneous urticaria present a positive response to the intradermal injection of their own serum (serum autoreactivity) in the autologous serum skin test (ASST). However, only a minority of these patients have detectable antibodies to the FC¿RI or to autologous IgE (autoimmunity). Chronic autoimmune urticaria accounts for 30% to 50% of all cases of CU.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In chronic autoimmune urticaria the cutaneous mast cells become permanently activated due to the presence of functional IgG antibodies to the alfa subunit of the FC¿RI (30%-50%) or to the IgE of the mast cell directly (5%-10%). Basophils also express FC¿RI, and thus a fall in basophil levels is usually detected in patients with chronic autoimmune urticaria. The capacity of the patient's serum to induce the degranulation of healthy basophils can be demonstrated by the in vitro detection of functional antibodies. It has recently been reported that IgE antithyroperoxidase antibodies can also induce mast-cell degranulation. Mast-cell degranulation is also thought to be induced by the classic complement pathway, particularly factor C5A, which, apart from favoring mast-cell and basophil degranulation, is involved in chemotaxis to recruit neutrophils, eosinophils, and monocytes. Antithyroid antibodies are detected in 25% of cases of chronic autoimmune urticaria (in contrast to 6% of the general population) and this form of urticaria has frequently been associated with diseases such as Hashimoto thyroiditis and, less commonly, with Graves disease; its association with other autoimmune diseases, such as diabetes mellitus and vitiligo, has also been reported.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">General Bases for the Treatment of Chronic Urticaria</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">General Measures</span><p id="par0030" class="elsevierStylePara elsevierViewall">In the treatment of urticaria it is important to avoid possible nonspecific triggers or aggravating factors such as heat, stress, alcohol, and certain drugs, including acetylsalicylic acid, NSAIDs, angiotensin-converting enzyme (ACE) inhibitors (particularly if the urticaria presents with angioedema, with or without wheals) and codeine. Cooling, antipruritic lotions such as calamine or 1% menthol in aqueous cream can be applied.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3,10,11</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Pharmacological Treatment</span><p id="par0035" class="elsevierStylePara elsevierViewall">The treatments of CU can be classified according to their different functional effects. The majority of drugs modulate the capacity of mast cells to undergo degranulation and release their mediators. This group includes certain antihistamines, the corticosteroids, ciclosporin A (CsA), tacrolimus, methotrexate, and phototherapy. Drugs routinely used in the treatment of CU act by blocking the receptors and modulating the mediators that, situated on the nerve fibers and blood vessels, induce pruritus, vasodilatation, and chemotaxis. These are the most widely used drugs in the management of CU and include the antihistamines (H<span class="elsevierStyleInf">1</span> and H<span class="elsevierStyleInf">2</span> blocking agents), antileukotrienes, and dapsone. Some drugs act prior to activation of the effector cell or mast cell. This group includes omalizumab (a monoclonal antibody with the ability to bind IgE), plasmapheresis, and intravenous immunoglobulins (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Antihistamines</span><p id="par0040" class="elsevierStylePara elsevierViewall">Histamine plays a key role in the formation of the typical lesion of urticaria. It has been observed that patients with CU have higher local levels of histamine than healthy individuals both in affected skin and in healthy skin.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> There are 4 types of histamine receptor in the skin: the H<span class="elsevierStyleInf">1</span> receptors, found mainly in the endothelium, smooth muscle, and central nervous system; the H<span class="elsevierStyleInf">2</span> receptors, located also on the parietal cells of the digestive tract; the H<span class="elsevierStyleInf">3</span> receptors, present in the central nervous system and on the bronchial smooth muscle; and the H<span class="elsevierStyleInf">4</span> receptors, found on dendritic cells in the skin, and in the thymus, spleen, small bowel, and colon, and which are currently a subject of therapeutic research. The antihistamines are effective in the treatment of urticaria because of their antagonism of the H<span class="elsevierStyleInf">1</span> receptors.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Antihistamines have been used to treat CU for more than 60 years and continue to be the treatment of first choice. The majority of symptoms of urticaria are the result of the actions of histamine on the H<span class="elsevierStyleInf">1</span> receptors located on the endothelial cells (wheal) and on the sensory nerve endings (pruritus). The antihistamines act on the endothelium of the postcapillary venules, reducing extravasation and wheal formation, and on the afferent C nerve fibers of the skin, reducing pruritus. In addition, the effect of the antihistamines on cutaneous axonal reflexes reduces erythema. Many of the antihistamines have anti-inflammatory activity as they reduce the levels of preformed or newly formed cytokine mediators and cell adhesion molecules, leading to a reduction in the recruitment of inflammatory cells (lymphocytes, monocytes, neutrophils, eosinophils). These actions occur mainly through 2 mechanisms: stabilization of the basophil and mast-cell membranes by the H<span class="elsevierStyleInf">1</span>-antihistamines and the inhibition of cytoplasmic transcription factors such as nuclear factor kappa-B.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The antihistamines can be classified into anti-H<span class="elsevierStyleInf">1</span>, anti-H<span class="elsevierStyleInf">2</span>, anti-H<span class="elsevierStyleInf">3</span>, and anti-H<span class="elsevierStyleInf">4</span> according to the receptors on which they act. The antihistamines currently used for the treatment of CU are the first-generation H<span class="elsevierStyleInf">1</span>-antihistamines, the second-generation H<span class="elsevierStyleInf">1</span>-antihistamines, and the H2 antihistamines.</p><p id="par0055" class="elsevierStylePara elsevierViewall">The first-generation H<span class="elsevierStyleInf">1</span>-antihistamines have been used for many years to treat CU and other allergic disorders. They have anticholinergic effects and cross the blood-brain barrier, leading to sedative effects. These side effects can limit adherence to treatment, and such drugs are therefore usually reserved for cases in which the pruritic symptoms occur mainly at night (interference with sleep initiation) and in patients who do not respond to second-generation antihistamines. The first-generation H<span class="elsevierStyleInf">1</span>-antihistamines include hydroxyzine, diphenhydramine, ciproheptadine, and dexchlorpheniramine (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">The efficacy of the second-generation H<span class="elsevierStyleInf">1</span>-antihistamines has also been demonstrated in the symptomatic treatment of urticaria. Some, such as rupatadine, have even been found to have greater affinity for binding to the histamine receptors than the first-generation H<span class="elsevierStyleInf">1</span>-antihistamines.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> They do not cross the blood-brain barrier and therefore do not give rise to sedative effects and they usually have no anticholinergic side effects. They are the only treatment with level 1 evidence and grade A recommendation. The second-generation H<span class="elsevierStyleInf">1</span>-antihistamines are currently the drugs of choice for the treatment of CU. However, symptoms persist in a large proportion of patients despite treatment with antihistamines at the recommended doses. In a recent study performed by Maurer et al.,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> up to 50% of patients with CU did not respond to the recommended doses of antihistamines, probably because those doses are based on the treatment of other allergic diseases, such as seasonal rhinitis. In nonresponders, it has been suggested that the dose of antihistamine be increased up to 4 times the recommended dose. Other mediators released by the mast cells, such as cytokines, eicosanoids, proteases, and PAF, have been implicated in the formation of wheals in patients with CU.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> It has recently been observed that PAF can induce mast-cell degranulation in vitro.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> The authors of this paper have been able to study the specific characteristics of the wheal induced by PAF in healthy volunteers; in this context, the wheal developed independently of mast-cell degranulation.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Two potent second-generation H<span class="elsevierStyleInf">1</span>-antihistamines, terfenadine and astemizole, were withdrawn from the market due to the appearance of cardiac side effects (ventricular arrhythmias-torsade de pointes). Since that time, both the Food and Drug Administration and the European Medicines Agency require cardiotoxicity studies to be performed during the development of any new antihistamine.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Numerous clinical trials have been performed to compare the different second-generation antihistamines against each other and against placebo. No statistically significant differences were detected with regard to symptom control, safety profile, or quality of life.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,18–22</span></a> A description of the second-generation H<span class="elsevierStyleInf">1</span>-antihistamines is given below.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Acrivastine</span><p id="par0075" class="elsevierStylePara elsevierViewall">Acrivastine has a short half-life and must therefore be administered 3 times a day (the other antihistamines are usually recommended once a day). It has a rapid onset of action. Acrivastine is excreted intact in the urine and its use must therefore be avoided in patients with moderate kidney failure.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Cetirizine</span><p id="par0080" class="elsevierStylePara elsevierViewall">Cetirizine is the active metabolite of hydroxyzine and it can therefore present sedative effects, particularly at high doses. Cetirizine reaches its maximum plasma concentration very quickly, which can be an important clinical advantage due to its rapid bioavailability. It has antiallergic effects on inflammatory mediators released by mast cells, particularly at high doses. Cetirizine must be avoided in cases of severe kidney failure.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Levocetirizine</span><p id="par0085" class="elsevierStylePara elsevierViewall">Levocetirizine is the active enantiomer of cetirizine. It is more potent.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> It has a higher potency than other antihistamines for the inhibition of wheal and of erythema after the intradermal injection of histamine.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Loratadine</span><p id="par0090" class="elsevierStylePara elsevierViewall">Loratadine undergoes first-pass metabolism in the liver, where it is transformed into its active molecule, desloratadine. It has antiallergic properties.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Desloratadine</span><p id="par0095" class="elsevierStylePara elsevierViewall">Desloratadine is the active metabolite of loratadine, and it is therefore more potent. It has a longer elimination half-life than loratadine (27<span class="elsevierStyleHsp" style=""></span>hours), and its administration must therefore be stopped 6 days before performing skin prick tests. It binds selectively and with high affinity to the H<span class="elsevierStyleInf">1</span> receptors. Desloratadine also has anti-inflammatory and antiallergic activity as it acts on cytokines and cell adhesion molecules. It inhibits other mediators implicated in the appearance of wheals, including cytokines IL-4, IL-13, IL-6, TNF, and GM-CSF, chemokines such as IL-8 and RANTES (regulated on activation, normal T-cell expressed and secreted), and adhesion molecules such as P-selectin and intercellular adhesion molecule (ICAM) 1. It reduces eosinophil chemotaxis and activation in vitro.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">27,28</span></a> Both desloratadine and loratadine must be used with caution in patients with severe kidney failure.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Mizolastine</span><p id="par0100" class="elsevierStylePara elsevierViewall">Mizolastine is contraindicated in clinically significant heart disease as it can cause prolongation of the QT interval. It must not be administered concomitantly with drugs that inhibit liver metabolism via the cytochrome P450 pathway (including macrolide antibiotics and imidazole antifungal drugs) or with potentially arrhythmogenic drugs (including tricyclic antidepressants such as doxepin). Its use is contraindicated in cases of liver failure.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Ebastine</span><p id="par0105" class="elsevierStylePara elsevierViewall">Ebastine is a second-generation H<span class="elsevierStyleInf">1</span>-antihistamine with a structure based on oxopiperidine. It undergoes first-pass metabolism in the liver; its active form is carebastine. It is mainly excreted in the urine. Ebastine produces a dose-dependent inhibition of histamine release by cutaneous mast cells. It has activity on H<span class="elsevierStyleInf">1</span> receptors and also inhibits the release of inflammatory mediators by mast cells.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,29</span></a> The usual dose of 10<span class="elsevierStyleHsp" style=""></span>mg must be adjusted in patients with kidney or liver failure.</p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Rupatadine</span><p id="par0110" class="elsevierStylePara elsevierViewall">Rupatadine is a new second-generation antihistamine with a long half-life. It is a dual antagonist of the peripheral H<span class="elsevierStyleInf">1</span> receptors and of PAF. Rupatadine competitively inhibits PAF-induced platelet aggregation in vitro, although to a lesser extent than its specific antagonist. Rupatadine also has anti-inflammatory properties: it inhibits eosinophil chemotaxis in vivo and in vitro, it suppresses the synthesis of inflammatory cytokines by activated T lymphocytes in vitro, and it interferes with cutaneous mast-cell degranulation and the release of histamine and other cytokines.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15,22,30,31</span></a> It is indicated for the treatment of CU and allergic rhinitis. The usual dose is 10<span class="elsevierStyleHsp" style=""></span>mg. The proportion of patients with CU who respond to rupatadine rises significantly if the dose is doubled to 20<span class="elsevierStyleHsp" style=""></span>mg. It is a safe and well-tolerated drug.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Fexofenadine</span><p id="par0115" class="elsevierStylePara elsevierViewall">Fexofenadine is a potent antihistamine that is selective for the peripheral H<span class="elsevierStyleInf">1</span> receptors. It is an effective drug for the treatment of both CU and allergic rhinitis<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">There is controversy concerning the role of the H<span class="elsevierStyleInf">2</span>-antihistamines in the treatment of CU. The cutaneous blood vessels have both H<span class="elsevierStyleInf">1</span> and H<span class="elsevierStyleInf">2</span> receptors and the activation of either type will induce the formation of wheal and erythema, although activation of the H<span class="elsevierStyleInf">2</span> receptors has a limited pruritic effect. The efficacy of combinations of H<span class="elsevierStyleInf">1</span>-antihistamines with H<span class="elsevierStyleInf">2</span>-antihistamines has been evaluated in a number of studies and a possible synergic effect has been reported. However, this association does not appear to be justified for the treatment of CU as efficacy has not been shown to be significantly better. The H<span class="elsevierStyleInf">2</span>-antihistamines include cimetidine, ranitidine, nizatidine, and famotidine.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,18</span></a></p><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Special Situations<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–4,10,11,13,18,23</span></a></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Pregnancy and Breastfeeding</span><p id="par0125" class="elsevierStylePara elsevierViewall">The use of any drug, including the antihistamines, should be avoided if possible during pregnancy, especially during the first trimester. The antihistamines are in pregnancy categories B and C. The second-generation antihistamines sertraline and loratadine are in category B (no evidence of fetal damage during pregnancy). Because of the greater cumulative experience, the prescription of first-generation H<span class="elsevierStyleInf">1</span>-antihistamines such as chlorpheniramine is usually recommended. If an antihistamine has to be used during breastfeeding, once again cetirizine and loratadine are recommended, at the lowest possible dose.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Childhood</span><p id="par0130" class="elsevierStylePara elsevierViewall">All the antihistamines can be used in children over 12 years of age. Cetirizine, loratadine, and desloratadine are authorized for the treatment of CU in children over 2 years of age.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Kidney and Liver Failure</span><p id="par0135" class="elsevierStylePara elsevierViewall">The antihistamines that are excreted mainly in the urine are cetirizine (60%) and levocetirizine (85%). The urinary excretion of the other second-generation antihistamines is only of the order of 10% to 20%. The metabolism of the majority of these drugs usually involves first-pass metabolism in the liver via the cytochrome P-450 or CYP pathway, with the exception of cetirizine, levocetirizine, fexofenadine, and desloratadine. In any case, a dose reduction of all second-generation H<span class="elsevierStyleInf">1</span>-antihistamines is recommended in patients with severe kidney or liver disease.</p></span></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Tricyclic Antidepressants</span><p id="par0140" class="elsevierStylePara elsevierViewall">The tricyclic antidepressants such as amitriptyline and, in particular, doxepin, have been widely used in the treatment of CU for their potent H<span class="elsevierStyleInf">1</span>- and H<span class="elsevierStyleInf">2</span>-antihistamine effect. However, their use is limited by their sedative and anticholinergic effects, which are potentiated by the use of alcohol, and by the relative risk of cardiac arrhythmias secondary to prolongation of the QT interval. Administration at night is usually recommended because of their sedative effects, and they are particularly useful in patients with concomitant depression. Doxepin is used at doses of 10-30<span class="elsevierStyleHsp" style=""></span>mg for the treatment of CU.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,18</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Antileukotrienes</span><p id="par0145" class="elsevierStylePara elsevierViewall">The most widely used antileukotriene is montelukast, a leukotriene-receptor antagonist that has been used in the treatment of asthma and urticaria. There is very little evidence of its efficacy in monotherapy.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3,10,33,34</span></a> These drugs can be combined with antihistamines in treatment-resistant urticaria. Although the response to these drugs is not highly predictable, there are studies that suggest that montelukast may be effective in the treatment of autoimmune urticaria, delayed pressure urticaria, and in urticaria complicated by intolerance to acetylsalicylic acid or to food coloring agents, but it has no or almost no demonstrated efficacy in chronic idiopathic urticaria. Montelukast has been used to treat eosinophilic urticaria (eosinophilic infiltrate present on skin biopsy) as activated eosinophils induce the synthesis of eicosanoid mediators generated from arachidonic acid and leukotrienes, particularly LTC4, LTD4, and LTE3. The leukotrienes act by attracting cells to sites of inflammation and thus intensifying the inflammatory response.</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Corticosteroids</span><p id="par0150" class="elsevierStylePara elsevierViewall">No controlled studies have been performed on the use of corticosteroids for the treatment of urticaria or angioedema, but they are generally accepted as effective (grade D recommendation). They should be prescribed in short cycles and in tapering regimens for the treatment of severe exacerbations of CU, particularly when the condition is associated with angioedema, due to the risk of secondary respiratory difficulty. They may also be administered when difficulty is experienced in controlling symptoms with antihistamines in monotherapy or when a more rapid clinical improvement is sought. Corticosteroids have also been used for the treatment of urticarial vasculitis. The minimum effective dose should be administered and prolonged treatment should be avoided in order to avoid their side effects. Topical corticosteroids should not be used in CU.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Ciclosporin A</span><p id="par0155" class="elsevierStylePara elsevierViewall">CsA is an inhibitor of calcineurin, a protein with phosphatase activity that permits nuclear factor of T cells to pass from the cytoplasm into the nucleus, with expression of the IL-2 gene that activates T cells and stimulates the secretion of interferon-γ and GM-CSF. CsA therefore acts by blocking the synthesis of IL-2, giving rise to a state of cellular and humoral immunosuppression.<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">35,36</span></a> The main side effects of CsA are neurotoxicity and systemic hypertension (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). In the management of CU, CsA is indicated in patients with severe CU with a positive ASST and who have not responded to antihistamines. It is used at doses of 3-5<span class="elsevierStyleHsp" style=""></span>mg/kg/d for periods of at least 2 months. The optimal dose and duration of treatment have not yet been defined nor do we have criteria for predicting a response.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> Responses have been observed in patients with chronic spontaneous urticaria (with no evidence of functional antibodies, thus ASST negative), although this is not as well documented in the literature and the effects of treatment are less predictable than in patients with chronic autoimmune urticaria.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a></p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Tacrolimus</span><p id="par0160" class="elsevierStylePara elsevierViewall">Tacrolimus has been used successfully to treat corticosteroid-dependent CU at doses of 0.5-2<span class="elsevierStyleHsp" style=""></span>mg/kg/d in 2 daily doses. It acts by inhibiting T lymphocytes and reducing the release of inflammatory cytokines.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a></p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Mycophenolate Mofetil</span><p id="par0165" class="elsevierStylePara elsevierViewall">Mycophenolate mofetil is an immunomodulator drug that acts by inhibiting DNA synthesis in lymphocytes. It is a reversible inhibitor of inosine monophosphate dehydrogenase (present exclusively in lymphocytes and involved in purine synthesis). In CU, mycophenolate mofetil inhibits the production of antibodies to the high-affinity IgE receptor or to IgE itself. It also reduces the expression of adhesion molecules on in endothelial cells and inhibits lymphocyte migration towards the skin.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">40</span></a> In both autoimmune and idiopathic CU, mycophenolate mofetil has been found to be effective in reducing pruritus, the duration of the episode, the number of wheals, and the number of episodes of urticaria or angioedema. Complete remission has been reported in some cases. Mycophenolate mofetil has been used at doses of 500<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h for 2 to 4 weeks. It is a safe drug with few side-effects, which are mainly gastrointestinal at the doses used for the treatment of CU, and they can improve with time.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">41</span></a></p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Cyclophosphamide</span><p id="par0170" class="elsevierStylePara elsevierViewall">Good results have been reported with intravenous cyclophosphamide; some patients with corticosteroid-dependent urticaria have achieved complete remission.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a></p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Methotrexate</span><p id="par0175" class="elsevierStylePara elsevierViewall">Methotrexate can be useful in some cases as a corticosteroid-saving drug in patients with corticosteroid-dependent CU. It is used at doses of 10-15<span class="elsevierStyleHsp" style=""></span>mg per week.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a> The response does not appear to be related to the presence or absence of antibodies in the serum. The response is thought to be more closely related to its anti-inflammatory than to its immunosuppressant effect and it is therefore as successful in the treatment of chronic idiopathic urticaria as in chronic autoimmune urticaria.</p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Tumor Necrosis Factor Inhibitors</span><p id="par0180" class="elsevierStylePara elsevierViewall">Little has been published in the literature about the treatment of CU with TNF inhibitors. Magerl et al.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a> described the case of a patient with psoriasis and delayed pressure CU in which treatment with etanercept achieved a rapid and lasting improvement.</p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Phototherapy</span><p id="par0185" class="elsevierStylePara elsevierViewall">Phototherapy reduces the number of cutaneous mast cells in the superficial dermis.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">45</span></a> It has been used for the treatment of idiopathic CU and in symptomatic dermographism. UV-A, UV-B, or narrowband UV-B can be used for periods of 1 to 3 months. Narrowband UV-B has achieved good results as adjuvant therapy in combination with antihistamines. Long-term efficacy (up to 3 months after of the end of treatment) has been observed in some cases.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">46</span></a></p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Intravenous Immunoglobulin</span><p id="par0190" class="elsevierStylePara elsevierViewall">The indications for intravenous immunoglobulin approved by the Food and Drug Administration are primary immunodeficiencies, secondary immunodeficiencies, Kawasaki disease, and idiopathic thrombocytopenic purpura.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a> In CU, intravenous immunoglobulin has been used mainly for chronic autoimmune urticaria refractory to other treatments. O’Donell et al.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> treated 10 patients with severe chronic autoimmune urticaria with intravenous immunoglobulin at doses of 400<span class="elsevierStyleHsp" style=""></span>mg/kg/d for 5 days, achieving a clinical improvement in 9 of them—in 3 of those patients there was a long-term improvement. A good response has also been reported in some patients with delayed pressure urticaria and solar urticaria.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> The mechanism of action is not fully understood, but it has been suggested that intravenous immunoglobulin may contain anti-idiotypic antibodies that compete with endogenous IgG for the H<span class="elsevierStyleInf">1</span> receptors, blocking histamine release. Saturation of the Fc receptors by immunoglobulin prevents IgE from binding to the cutaneous mast cells and thus inhibits histamine release and the appearance of wheals. It is not known why the effect persists over time. The cost of treatment is high and it has an elevated morbidity. There are no controlled studies.</p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Plasmapheresis</span><p id="par0195" class="elsevierStylePara elsevierViewall">Plasmapheresis is an extracorporeal blood purification technique that consists of the separation of the plasma from the cellular components of the blood with the aim of removing the pathogenic elements causing the disease; in the case of CU, these elements are the histamine-releasing antibodies. Plasmapheresis has been used in cases of treatment-resistant CU,<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> although no controlled clinical trials have been performed. The cost of plasmapheresis is high and there is potential morbidity. Recurrence is common. In monotherapy, plasmapheresis is not sufficient to prevent the re-accumulation of histamine-releasing antibodies and it must be used in combination with immunosuppressant drugs.</p></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Omalizumab</span><p id="par0200" class="elsevierStylePara elsevierViewall">Omalizumab is a humanized recombinant monoclonal antibody that binds specifically to the C3¿ domain of the IgE heavy chain, the site that binds to the high-affinity IgE receptors on the surface of mast cells and basophils. It is currently only authorized for use in severe allergic asthma.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">There are 2 types of IgE receptors<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a>: the FC¿RI receptor present on mast cells, basophils, monocytes, eosinophils, and Langerhans cells; and the low-affinity receptors (FC¿RII/CD23), involved in antigen presentation (FC¿RII on B lymphocytes) and in the regulation of IgE synthesis. Omalizumab reduces the levels of free circulating IgE and secondarily reduces the density of IgE receptors on basophils and cutaneous mast cells, preventing their antibody-induced activation and degranulation. IgE can modulate the level of expression of its own high-affinity and low-affinity receptors. When IgE binds to FC¿RI on mast cells and basophils, it determines the levels of expression of the surface receptors, such that a higher concentration of IgE will increase the density of its receptors (and, hence, mast cell and basophil reactivity), whilst a lower concentration will reduce receptor density. When IgE binds to FC¿RI, an interaction occurs between the C3 domain of IgE and the α-chain of the receptor.<a class="elsevierStyleCrossRefs" href="#bib0260"><span class="elsevierStyleSup">52–57</span></a> Omalizumab may also act by reducing the number of IgE antithyroperoxidase autoantibodies, producing an inhibition of mast-cell degranulation by reducing the density of IgE receptors on their surface (negative feedback).<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">It has been observed that omalizumab is not only successful in the treatment of chronic autoimmune urticaria, but that it may also have a role in chronic idiopathic urticaria (ASST negative disease with no histamine release by basophils in vitro). This effect may be due to a direct action on mast cells, eosinophils, or basophils, even in the absence of autoantibodies. Another possible explanation is that omalizumab may prevent the FC¿RI-dependent secretion of cytokines and chemokines through some as yet unknown stimulus. A good response has been observed in physical urticarias (solar urticaria, heat urticaria, cold urticaria, delayed pressure urticaria, and cholinergic urticaria), although we only have isolated case reports and a larger number of studies are necessary to evaluate its potential efficacy.<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">58–63</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">In the treatment of severe allergic asthma, omalizumab is administered by subcutaneous injection at doses that vary between 75<span class="elsevierStyleHsp" style=""></span>mg and 375<span class="elsevierStyleHsp" style=""></span>mg, depending on body weight and IgE levels in the blood. In a recent study by Saini et al.,<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">64</span></a> a frank improvement in the urticaria activity score 7 (UAS7) with respect to baseline was observed 4 weeks after a single dose of 300<span class="elsevierStyleHsp" style=""></span>mg or 600<span class="elsevierStyleHsp" style=""></span>mg of omalizumab, and the treatment was more successful than placebo, with a rapid onset of effects (first week). However, no statistically significant difference with respect to placebo was observed with a dose of 75<span class="elsevierStyleHsp" style=""></span>mg. Taking into account that it is necessary to wait for up to 16 weeks to observe a response after the treatment of allergic asthma, it has been suggested that omalizumab could have an effect not only on IgE, but also a direct effect on mast cells.</p><p id="par0220" class="elsevierStylePara elsevierViewall">In several studies it has been found that omalizumab reduces the UAS and the need for rescue medication and that it increases the therapeutic response and improves the quality of life of patients with CU.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> The side effects described are mostly mild (rhinopharyngitis, diarrhea, headache, local symptoms at the site of injection) although they can be more severe in occasional cases (anaphylaxis).</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Other Treatments</span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0185">Nifedipine</span><p id="par0225" class="elsevierStylePara elsevierViewall">The results on the use of nifedipine in the treatment of urticaria are contradictory. It has been reported to be effective in reducing pruritus and wheal formation in patients with CU when combined with high-dose antihistamines.<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">65</span></a> However, in other studies, nifedipine has been found to have little effect on CU.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> Nifedipine acts by modifying calcium entry into the cutaneous mast cells. It may be a drug to consider in patients with systemic hypertension, particularly in those taking ACE inhibitors.</p></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0190">Anticoagulation and Antifibrinolysis</span><p id="par0230" class="elsevierStylePara elsevierViewall">In some patients with CU, thrombin levels have been found to be elevated due to activation of the coagulation cascade via the extrinsic pathway, and signs of fibrinolysis with elevated plasma D-dimer levels were also observed. This occurred in more severe cases of CU with a poorer response to first-line treatment with antihistamines.<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">66–69</span></a> It has been suggested that thrombin could increase vascular permeability, activating mast-cell degranulation and the complement cascade in the absence of C3. Activation of the coagulation cascade in these patients is associated with a poorer response to treatment with antihistamines at approved doses. D-dimer levels could serve as a marker to identify this group of patients with chronic idiopathic urticaria. In these patients, combined treatment with an anticoagulant (heparin) and an antifibrinolytic (tranexamic acid) could be useful, as this situation affects a subgroup of patients in whom we would be blocking a mechanism of activation of inflammation.<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">70</span></a></p></span><span id="sec0175" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0195">Dapsone</span><p id="par0235" class="elsevierStylePara elsevierViewall">Dapsone (4-49-diaminodiphenylsulfone) is a sulfone derivative that has antimicrobial and anti-inflammatory effects and has been used for many years to treat a wide variety of skin diseases with neutrophilic dermal infiltrates, including urticarial vasculitis, Behçet disease, and pyoderma gangrenosum. Dapsone alone or combined with other treatments is considered a therapeutic option for the treatment of urticaria. Anecdotally, there have been occasional reports of an improvement in chronic idiopathic urticaria and delayed pressure urticaria.<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">71</span></a></p></span><span id="sec0180" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0200">Colchicine</span><p id="par0240" class="elsevierStylePara elsevierViewall">Colchicine has been widely used for the treatment of a heterogeneous group of skin diseases typically characterized by the presence of neutrophilic dermal infiltrates, including psoriasis, leukocytoclastic vasculitis, and urticarial vasculitis. Colchicine limits the chemotactic and phagocytic activity of neutrophils and suppresses leukocyte function by increasing the levels of cyclic adenosine monophosphate in the cytoplasm and by inhibiting lysosome degranulation.<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">72,73</span></a> The increased levels of cyclic adenosine monophosphate release prostaglandin<span class="elsevierStyleHsp" style=""></span>E, which suppresses leukocyte function. Oka et al.<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">74</span></a> demonstrated that colchicine causes the depolymerization of microtubules crucial for mast-cell degranulation. The inhibitory effect of colchicine in urticaria could be due to a dual effect: chemotactic blockade of the neutrophils and reduced mast-cell degranulation. It has occasionally been used in patients with urticarial vasculitis.</p></span><span id="sec0185" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0205">Sulfasalazine</span><p id="par0245" class="elsevierStylePara elsevierViewall">Sulfasalazine belongs to a group of antifolate drugs and has been used for many years in the treatment of inflammatory bowel diseases and rheumatoid arthritis. Its main side effects are liver toxicity, neurotoxicity, and myelotoxicity. The mechanism of action of sulfasalazine in CU is unknown. It may affect IgE-mediated histamine release and reduce the activity of prostaglandin synthetase. It could be useful as a corticosteroid-saving drug.<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">75</span></a> There are few controlled studies on its use in CU.</p></span><span id="sec0190" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0210">Hydroxychloroquine</span><p id="par0250" class="elsevierStylePara elsevierViewall">Hydroxychloroquine has been used in the treatment of hypocomplementemic urticarial vasculitis syndrome.<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">76</span></a></p></span></span><span id="sec0195" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0215">Recommendations of the European Guidelines</span><p id="par0255" class="elsevierStylePara elsevierViewall">The management and treatment of patients with CU is complex. For this reason, consensus guidelines based on scientific evidence and on expert opinion have been drawn up for the management of this disease. The 2 existing guidelines for the management of CU are the “BSACI guidelines for the management of chronic urticaria and angio-oedema,” drawn up by the British Society for Allergy and Clinical Immunology<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> (BSACI) and published in <span class="elsevierStyleItalic">Clinical and Experimental Allergy</span> in 2007, and the European guidelines of the EAACI/GA2LEN/EDF/WAO, published in <span class="elsevierStyleItalic">Allergy</span> in 2009.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> The European guidelines are the result of the consensus reached by a discussion panel at the Third International Consensus Meeting on Urticaria in 2008 by the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO).</p><p id="par0260" class="elsevierStylePara elsevierViewall">The main difference between the 2 guidelines in the treatment algorithm for CU is that the British guidelines continue to recommended the use of sedative antihistamines at night if nonsedative antihistamines have not been effective, even at high doses, whereas the European guidelines do not recommend these drugs in any case<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,10</span></a> (<a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1 and 2</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0265" class="elsevierStylePara elsevierViewall">In November 2012, in Berlin, at the fourth consensus meeting to update the guidelines for chronic spontaneous urticaria, certain changes were introduced into the management algorithm for CU. As the algorithm only included those treatment options supported by a high level of recommendation, the use of dapsone and of the H<span class="elsevierStyleInf">2</span>-antihistamines was withdrawn. In view of the failure of the use of the nonsedative H<span class="elsevierStyleInf">1</span>-antihistamines at the approved doses, an increase of up to 4 times that dose was recommended. Omalizumab, ciclosporin A, and the antileukotrienes continue to figure as second-line treatment. These drugs are used in addition to the H<span class="elsevierStyleInf">1</span>-antihistamines. However, reading of the entire guidelines is recommended as the use of other therapeutic options that do not figure in the algorithm is not rejected for certain patients (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0200" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0220">Ethical Disclosures</span><span id="sec0205" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0225">Protection of human and animal subjects</span><p id="par0270" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were performed on humans or animals for this investigation.</p></span><span id="sec0210" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0230">Confidentiality of data</span><p id="par0275" class="elsevierStylePara elsevierViewall">The authors declare that no private patient data are disclosed in this article.</p></span><span id="sec0215" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0235">Right to privacy and informed consent</span><p id="par0280" class="elsevierStylePara elsevierViewall">The authors declare that no private patient data are disclosed in this article.</p></span></span><span id="sec0220" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0240">Conflicts of Interest</span><p id="par0285" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:26 [ 0 => array:2 [ "identificador" => "xres342708" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec324324" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres342709" "titulo" => "Resumen" ] 3 => array:2 [ "identificador" => "xpalclavsec324325" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Etiological and Pathophysiological Aspects to Be Taken Into Account in the Treatment of Chronic Urticaria" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "General Bases for the Treatment of Chronic Urticaria" "secciones" => array:10 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "General Measures" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Pharmacological Treatment" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Antihistamines" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Acrivastine" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Cetirizine" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "Levocetirizine" ] 6 => array:2 [ "identificador" => "sec0045" "titulo" => "Loratadine" ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "Desloratadine" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "Mizolastine" ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "Ebastine" ] ] ] 6 => array:2 [ "identificador" => "sec0065" "titulo" => "Rupatadine" ] 7 => array:3 [ "identificador" => "sec0070" "titulo" => "Fexofenadine" "secciones" => array:1 [ 0 => array:3 [ "identificador" => "sec0075" "titulo" => "Special Situations" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0080" "titulo" => "Pregnancy and Breastfeeding" ] 1 => array:2 [ "identificador" => "sec0085" "titulo" => "Childhood" ] 2 => array:2 [ "identificador" => "sec0090" "titulo" => "Kidney and Liver Failure" ] ] ] ] ] 8 => array:2 [ "identificador" => "sec0095" "titulo" => "Tricyclic Antidepressants" ] 9 => array:2 [ "identificador" => "sec0100" "titulo" => "Antileukotrienes" ] 10 => array:2 [ "identificador" => "sec0105" "titulo" => "Corticosteroids" ] 11 => array:2 [ "identificador" => "sec0110" "titulo" => "Ciclosporin A" ] 12 => array:2 [ "identificador" => "sec0115" "titulo" => "Tacrolimus" ] 13 => array:2 [ "identificador" => "sec0120" "titulo" => "Mycophenolate Mofetil" ] 14 => array:2 [ "identificador" => "sec0125" "titulo" => "Cyclophosphamide" ] 15 => array:2 [ "identificador" => "sec0130" "titulo" => "Methotrexate" ] 16 => array:2 [ "identificador" => "sec0135" "titulo" => "Tumor Necrosis Factor Inhibitors" ] 17 => array:2 [ "identificador" => "sec0140" "titulo" => "Phototherapy" ] 18 => array:2 [ "identificador" => "sec0145" "titulo" => "Intravenous Immunoglobulin" ] 19 => array:2 [ "identificador" => "sec0150" "titulo" => "Plasmapheresis" ] 20 => array:2 [ "identificador" => "sec0155" "titulo" => "Omalizumab" ] 21 => array:3 [ "identificador" => "sec0160" "titulo" => "Other Treatments" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0165" "titulo" => "Nifedipine" ] 1 => array:2 [ "identificador" => "sec0170" "titulo" => "Anticoagulation and Antifibrinolysis" ] 2 => array:2 [ "identificador" => "sec0175" "titulo" => "Dapsone" ] 3 => array:2 [ "identificador" => "sec0180" "titulo" => "Colchicine" ] 4 => array:2 [ "identificador" => "sec0185" "titulo" => "Sulfasalazine" ] 5 => array:2 [ "identificador" => "sec0190" "titulo" => "Hydroxychloroquine" ] ] ] 22 => array:2 [ "identificador" => "sec0195" "titulo" => "Recommendations of the European Guidelines" ] 23 => array:3 [ "identificador" => "sec0200" "titulo" => "Ethical Disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0205" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0210" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0215" "titulo" => "Right to privacy and informed consent" ] ] ] 24 => array:2 [ "identificador" => "sec0220" "titulo" => "Conflicts of Interest" ] 25 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2012-09-19" "fechaAceptado" => "2012-12-25" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec324324" "palabras" => array:4 [ 0 => "Chronic spontaneous urticaria" 1 => "Autoimmune chronic urticaria" 2 => "Treatment" 3 => "Antihistamines" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec324325" "palabras" => array:4 [ 0 => "Urticaria crónica espontánea" 1 => "Urticaria crónica autoinmune" 2 => "Tratamiento" 3 => "Antihistamínicos" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Chronic spontaneous urticaria, also known as chronic idiopathic urticaria or simply chronic urticaria, is a common disorder that has a prevalence in the general population that ranges between 0.5% and 1%. This condition negatively affects the patient's quality of life and has considerable impact on direct and indirect health-related costs. Chronic urticaria is difficult to manage. Nonsedating H<span class="elsevierStyleInf">1</span> antihistamines are the first line of therapy, but fewer than 50% of patients experience relief at recommended dosages. Although guidelines call for increasing the dosage when response is inadequate, some patients still do not achieve adequate control of symptoms. New treatment alternatives, with proven efficacy under the standards of evidence-based medical practice, must therefore be developed.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La urticaria crónica espontánea, también conocida como urticaria crónica idiopática o urticaria crónica, es un proceso frecuente con una prevalencia estimada de entre el 0,5 y el 1% de la población general. Es un proceso que interfiere en la calidad de vida del paciente y ocasiona un notable impacto en los costes sanitarios directos e indirectos. La urticaria crónica es una entidad que plantea dificultades de manejo terapéutico. Se considera que los fármacos antihistamínicos H1 no sedantes son el tratamiento de primera elección. Su prescripción a las dosis recomendadas solo consigue una reducción de los síntomas en menos del 50% de los pacientes. Aunque las guías terapéuticas recomiendan incrementar las dosis en casos de respuestas no adecuadas, persiste un grupo de pacientes en los que no se consigue controlar la sintomatología. Existe, pues, la necesidad del desarrollo de nuevas alternativas terapéuticas cuya eficacia se establezca bajo criterios de medicina basada en la evidencia.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Please cite this article as: Curto-Barredo L, Silvestre JF, Giménez-Arnau AM. Actualización en el tratamiento de la urticaria crónica. Actas Dermosifiliogr. 2014;105:469–482.</p>" ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2333 "Ancho" => 2250 "Tamanyo" => 247740 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Treatment algorithm for chronic spontaneous urticaria based on the 2007 BSACI guidelines for the management of chronic urticaria and angioedema. Source: Standards of Care Committee, British Society for Allergy and Clinical Immunology, with permission.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1653 "Ancho" => 2499 "Tamanyo" => 209254 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Treatment algorithm for chronic spontaneous urticaria based on the 2009 European guidelines of the European Academy of Allergology and Clinical Immunology, the Global Allergy and Asthma European Network, the European Dermatology Forum, and the World Allergy Organization. With the permission of the authors. In the 2012 update consensus, the recommendation for the use of dapsone and H<span class="elsevierStyleInf">2</span>-antihistamines was withdrawn. Increases in the dose of nonsedative H<span class="elsevierStyleInf">1</span>-antihistamines of up to 4 times the approved doses was recommended and omalizumab, ciclosporin A, and antileukotrienes were maintained for second-line treatment.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 4333 "Ancho" => 2833 "Tamanyo" => 714773 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Algorithm for the management of patients with chronic spontaneous urticaria. Source: Maurer et al.,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> with the permission of the authors.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">QoL indicates quality of life; nsAH, nonsedating antihistamine.</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">a</span> Based on the algorithm for the management of patients with chronic spontaneous urticaria. Source: Maurer et al.,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> with permission.</p>" ] ] 3 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: LMWH, low-molecular-weight heparin; TNF, tumor necrosis factor.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">IgE Modulators \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Mast-Cell Modulators \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Receptors on Nerves and Blood Vessels, and Chemotaxis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Omalizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antihistamines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antihistamines \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Intravenous immunoglobulin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antileukotrienes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Plasmapheresis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ciclosporin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dapsone \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mycophenolate mofetil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tacrolimus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Colchicine \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Phototherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mycophenolate mofetil \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tranexamic acid<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>LMWH \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tranexamic acid<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>LMWH \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Interferon \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anti-TNF \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab508512.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Mechanism of Action of the Treatments for Chronic Urticaria.</p>" ] ] 4 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Family \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Active Substance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Mechanism of Action \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Side Effects \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Trade Name<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alkylamide (propylamine) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Dexchlorpheniramine maleate</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">H<span class="elsevierStyleInf">1</span>-receptor antagonist \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4-8<span class="elsevierStyleHsp" style=""></span>mg/6<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Somnolence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Polaramine \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Chlorpheniramine maleate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brompheniramine maleate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Aminoalkyl ether (ethanolamine) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Diphenhydramine hydrochloride</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">H<span class="elsevierStyleInf">1</span>-receptor antagonistAnticholinergicCough suppressant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25-50<span class="elsevierStyleHsp" style=""></span>mg/4<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SomnolenceGastrointestinal disturbancesDryness of mucosasBlurred visionHypotensionDifficulty urinating \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Benadryl \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clemastine fumarate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ethylenediamine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Tripelenamine hydrochloride</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antihistamine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25-50<span class="elsevierStyleHsp" style=""></span>mg/4<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SomnolenceGastrointestinal disturances \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pyribenzamine \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tripenelamine citrate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Phenothiazine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Promethazine hydrochloride</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">H<span class="elsevierStyleInf">1</span>-receptor antagonist \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25<span class="elsevierStyleHsp" style=""></span>mg/8<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SomnolenceAgranulocytosisLiver toxicityPhotosensitivity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fenergan \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Methdilazine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Methdilazine hydrochloride \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Piperidine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Ciproheptadine hydrochloride</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">H<span class="elsevierStyleInf">1</span>-receptor antagonistAntiserotoninergicAnticholinergic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4<span class="elsevierStyleHsp" style=""></span>mg/8<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SomnolenceCNS alterationsAuditory disturbancesCardiac disturbancesAgranulocytosisDryness of mucosasGastrointestinal disturbancesDifficulty urinating Photosensitivity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Periactin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Azatadine maleate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Piperazine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Hydroxyzine hydrochloride</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">H<span class="elsevierStyleInf">1</span>-receptor antagonistAntiadrenergicBronchodilatorAntiemetic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25<span class="elsevierStyleHsp" style=""></span>mg/6-8<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SomnolenceHeadacheFatigueDryness of the mouthSedation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Atarax \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab508513.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Names in bold correspond to the active substance of the drug whose trade name appears in the final column.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Trade names of drugs available in Spain</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Table Comparing the First-Generation H<span class="elsevierStyleInf">1</span> Antihistamines<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a></p>" ] ] 5 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: GM-CSF, granulocyte-macrophage colony stimulating factor; ICAM, intercellular adhesion molecule; IL, interleukin; LTC4, leukotriene C4; MCP1, monocyte chemoattractant protein-1; NF-kB, nuclear factor–kappa B; PAF, platelet activation factor; RANTES, regulated and normal T-cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Family \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Active Substance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Mechanism of Action \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Side Effects \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Trade Name<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Piperidine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mizolastine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neutrophil recruitment5-lipooxigenaseVEGF, TNF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prolongation of the QT intervalGastrointestinal disturbancesDryness of the mouth, somnolence, headacheIncreased appetite \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MizolenZolistan \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Terfenadine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Eosinophil chemotaxisEosinophil adherenceSuperoxide synthesisIL-6, IL-8, TNFGM-CSF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60-120<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CardiotoxicityHeadache, vertigoIncreased sweatingDigestive disturbancesSedation, dryness of the mouth \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Triludan \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fexofenadine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">180<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache, dizziness, somnolence, fatigue, dryness of the mouth, nausea \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Telfast \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Loratadine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Eosinophil chemotaxisIL-8, RANTES, ICAM-1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Somnolence/insomnia, headache, increased appetite \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clarytine \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Desloratadine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Eosinophil chemotaxisSuperoxide productionTNF, IL-1, IL-6, IL-8, IL-13P-selectin, ICAM-1Eosinophil apoptosisNK-kB cell activation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Tiredness, dryness of the mouthHeadache \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AeriusAzomyr \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rupatadine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PAF, TNF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Somnolence, headache, fatigue \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RupafinAlergoliber, Rinialer \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ebastine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AntihistamineAntiallergic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10-20<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache, somnolence, fatigue, dryness of the mouth, rhinitis, pharyngitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ebastel \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alkylamine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acrivastine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16-24<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Piperazine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cetirizine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Eosinophil adhesionEosinophil and neutrophil chemotaxisT-cell and monocyte chemotaxisIL-8, MCP1/RANTES NF-kB 19ICAM-1LTC4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Headache, somnolence, fatigueDryness of the mouthGastrointestinal disturbances \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ZyrtecAlerlisinVirlix \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Levocetirizine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">XazalAralevo \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab508514.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Trade names of drugs available in Spain</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Table Comparing the Second-Generation H<span class="elsevierStyleInf">1</span> Antihistamines.</p>" ] ] 6 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Absolute Contraindications \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Relative Contraindications \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Poorly controlled hypertension \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><<span class="elsevierStyleHsp" style=""></span>18 years or<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>65 years \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Kidney failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Drug and alcohol abuse \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">History of malignancy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pregnancy or breastfeeding \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Uncontrolled infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Severe liver dysfunction \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No possibility of follow-up \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Primary or secondary immunodeficiency \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Diabetes mellitus \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Epilepsy \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab508511.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Contraindications to Treatment With Ciclosporin A.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:76 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Zuberbier" 1 => "R. Asero" 2 => "C. Bindslev-Jensen" 3 => "C.G. Walter" 4 => "M.K. Church" 5 => "A. Gimenez-Arnau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2009.02179.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2009" "volumen" => "64" "paginaInicial" => "1417" "paginaFinal" => "1426" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19772512" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BSACI guidelines for the management of chronic urticaria and angio-oedema" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "British Society for Allergy and Clinical Immunology (BSACI)" "etal" => true "autores" => array:6 [ 0 => "R.J. Powel" 1 => "G.L. Du Toit" 2 => "N. Siddique" 3 => "S.C. Leech" 4 => "T.A. Dixon" 5 => "A.T. Clark" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2222.2007.02678.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Allergy" "fecha" => "2007" "volumen" => "37" "paginaInicial" => "631" "paginaFinal" => "650" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17456211" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urticaria. A review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T. Poonawalla" 1 => "B. Kelly" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "9" "paginaFinal" => "21" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19170406" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic urticaria: pathogenesis and treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.P. Kaplan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2004.02.049" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2004" "volumen" => "114" "paginaInicial" => "465" "paginaFinal" => "474" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15356542" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Unmet clinical needs in chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Maurer" 1 => "K. Weller" 2 => "C. Bindsley-Jensen" 3 => "A. Giménez-Arnau" 4 => "P.J. Bousquet" 5 => "J. Bousquet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2002" "volumen" => "109" "paginaInicial" => "114" "paginaFinal" => "118" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11799375" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y. Kikuchi" 1 => "A.P. Kaplan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2002" "volumen" => "109" "paginaInicial" => "114" "paginaFinal" => "118" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11799375" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology of urticaria in Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Gaig" 1 => "M. Olona" 2 => "D. Muñoz Lejarazu" 3 => "M.T. Caballero" 4 => "F.J. Domínguez" 5 => "S. Echechipia" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Investig Allergol Clin Immunol" "fecha" => "2004" "volumen" => "14" "paginaInicial" => "214" "paginaFinal" => "220" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of chronic urticaria on the quality of life" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "B.F. O’Donnell" 1 => "F. Lawlor" 2 => "J. Simpson" 3 => "M. Morgan" 4 => "M.W. Greaves" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "1997" "volumen" => "136" "paginaInicial" => "197" "paginaFinal" => "201" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9068731" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Grob" 1 => "J. Revuz" 2 => "J.P. Ortonne" 3 => "P. Auguier" 4 => "G. Lorette" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.06385.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "152" "paginaInicial" => "289" "paginaFinal" => "295" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15727641" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EAACI/GA2LEN/EDF guideline: management of urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Zuberbier" 1 => "R. Asero" 2 => "C. Bindslev-Jensen" 3 => "C.G. Walter" 4 => "M.K. Church" 5 => "A. Gimenez-Arnau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2009.02178.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2009" "volumen" => "64" "paginaInicial" => "1427" "paginaFinal" => "1443" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19772513" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management and diagnostic guidelines for urticaria and angio-oedema" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "British Association of Dermatologists" "etal" => false "autores" => array:3 [ 0 => "C. Grattan" 1 => "S. Powell" 2 => "F. Humphreys" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2001" "volumen" => "144" "paginaInicial" => "708" "paginaFinal" => "714" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11298527" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Skin histamine in chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Phanuphak" 1 => "A.L. Schocket" 2 => "C.M. Arroyave" 3 => "P.F. Kohler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "1980" "volumen" => "65" "paginaInicial" => "371" "paginaFinal" => "375" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7372956" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antihistamines in the treatment of chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Jáuregui" 1 => "M. Ferrer" 2 => "J. Montoro" 3 => "I. Dávila" 4 => "J. Bartra" 5 => "A. del Cuvillo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Investig Allergol Clin Immunol" "fecha" => "2007" "volumen" => "17" "paginaInicial" => "41" "paginaFinal" => "52" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18228682" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rupatadine in allergic rhinitis and chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Mullol" 1 => "J. Bousquet" 2 => "W.G. Bachert" 3 => "A. Canonica" 4 => "A. Gimenez-Arnau" 5 => "M.L. Kowalski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2008.01640.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "5" "paginaFinal" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18339040" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo controlled treatment with rupatadine 10 and 20<span class="elsevierStyleHsp" style=""></span>mg" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Gimenez-Arnau" 1 => "I. Izquierdo" 2 => "M. Maurer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2009.03289.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2009" "volumen" => "23" "paginaInicial" => "1088" "paginaFinal" => "1091" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19453774" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Activation of human mast cells through the platelet-activating factor receptor" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Kajiwara" 1 => "T. Sasaki" 2 => "P. Bradding" 3 => "G. Cruse" 4 => "H. Sagara" 5 => "K. Ohmori" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2010.01.056" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2010" "volumen" => "125" "paginaInicial" => "1137" "paginaFinal" => "1145" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20392487" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intradermal injections of platelet-activating factor (PAF) result in wheal-and-flare type skin reactions but do not induce mast cell degranulation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Krause" 1 => "E. Martinez-Escala" 2 => "M. Farré-Albadalejo" 3 => "M.K. Church" 4 => "M. Abajian" 5 => "A. Giménez-Arnau" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2011" "volumen" => "131" "numero" => "suppl 2" "paginaInicial" => "S14" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of urticaria. An evidence-based evaluation of antihistamines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.E. Lee" 1 => "H.I. Maibach" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2001" "volumen" => "2" "paginaInicial" => "27" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11702618" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D.L. Breneman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Pharmacother" "fecha" => "1996" "volumen" => "30" "paginaInicial" => "1075" "paginaFinal" => "1079" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8893110" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Staevska" 1 => "T.A. Popov" …4 ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2009.11.047" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2010" "volumen" => "125" "paginaInicial" => "676" "paginaFinal" => "682" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of the efficacy of levocetirizine 5<span class="elsevierStyleHsp" style=""></span>mg and desloratadine 5<span class="elsevierStyleHsp" style=""></span>mg in chronic idiopathic urticaria patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2008.01893.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2009" "volumen" => "64" "paginaInicial" => "596" "paginaFinal" => "604" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2500/aap.2009.30.3226" "Revista" => array:6 [ "tituloSerie" => "Allergy Asthma Proc" "fecha" => "2009" "volumen" => "30" "paginaInicial" => "366" "paginaFinal" => "376" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines for evaluation and management of urticaria in adults and children" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.08283.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2007" "volumen" => "157" "paginaInicial" => "1116" "paginaFinal" => "1123" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Drug" "fecha" => "1993" "volumen" => "46" "paginaInicial" => "1055" "paginaFinal" => "1080" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A double-blind, randomized, single dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine and placebo: suppression of histamine-induced wheal-and-flare response during 24<span class="elsevierStyleHsp" style=""></span>hours in healthy male subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1081-1206(10)61995-3" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2002" "volumen" => "88" "paginaInicial" => "190" "paginaFinal" => "197" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiallergic properties of loratadine: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Adv Ther" "fecha" => "1995" "volumen" => "12" "paginaInicial" => "283" "paginaFinal" => "298" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The pharmacologic profile of desloratadine: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Allergy" "fecha" => "2001" "volumen" => "56" "numero" => "Suppl. 65" "paginaInicial" => "7" "paginaFinal" => "13" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Desloratadine in the treatment of chronic idiopathic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2001" "volumen" => "56" "paginaInicial" => "28" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ebastine in allergic rhinitis and chronic idiopathic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "1" "paginaFinal" => "20" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Rupatadine Urticaria Study Group" "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2007.01330.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2007" "volumen" => "62" "paginaInicial" => "539" "paginaFinal" => "546" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rupatadine for the treatment of allergic rhinitis and urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/eci.10.85" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Clin Immunol" "fecha" => "2011" "volumen" => "7" "paginaInicial" => "15" "paginaFinal" => "20" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int Arch Allergy Immunol" "fecha" => "2011" "volumen" => "156" "paginaInicial" => "1" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recent advances in antileukotriene therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ACI.0b013e32833bfa20" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Allergy Clin Immunol" "fecha" => "2010" "volumen" => "10" "paginaInicial" => "370" "paginaFinal" => "376" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546630802607495" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2009" "volumen" => "20" "paginaInicial" => "194" "paginaFinal" => "197" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "In vivo characterization of the anti-inflammatory effect of cyclosporine A on human basophils" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Immunol" "fecha" => "1993" "volumen" => "151" "paginaInicial" => "5563" "paginaFinal" => "5573" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-inflammatory effect of cyclosporin A on human skin mast cells" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "1992" "volumen" => "98" "paginaInicial" => "800" "paginaFinal" => "804" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Allergy Asthma Proc" "fecha" => "2003" "volumen" => "24" "paginaInicial" => "285" "paginaFinal" => "290" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2000" "volumen" => "143" "paginaInicial" => "365" "paginaFinal" => "372" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of patients with chronic idiopathic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1385/CRIAI:23:2:233" "Revista" => array:6 [ "tituloSerie" => "Clin Rev Allergy Immunol" "fecha" => "2002" "volumen" => "23" "paginaInicial" => "233" "paginaFinal" => "241" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2006.02655.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2006" "volumen" => "45" "paginaInicial" => "1224" "paginaFinal" => "1227" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: Experience in 19 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2011.06.004" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2011" "volumen" => "66" "paginaInicial" => "767" "paginaFinal" => "770" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1081-1206(10)61941-2" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2002" "volumen" => "89" "paginaInicial" => "212" "paginaFinal" => "214" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09538.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2010" "volumen" => "162" "paginaInicial" => "191" "paginaFinal" => "194" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of delayed pressure urticaria with anti-TNF-alfa" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2006.12.658" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2007" "volumen" => "119" "paginaInicial" => "752" "paginaFinal" => "754" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultraviolet light therapy in chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "1985" "volumen" => "65" "paginaInicial" => "449" "paginaFinal" => "450" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-0434" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2008" "volumen" => "88" "paginaInicial" => "247" "paginaFinal" => "251" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inmunoglobulina endovenosa en enfermedades neuromusculares. Guías para su utilización" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Neurol Arg" "fecha" => "2006" "volumen" => "31" "paginaInicial" => "32" "paginaFinal" => "46" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intravenous immunoglobulin in autoimmune chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "1998" "volumen" => "138" "paginaInicial" => "101" "paginaFinal" => "106" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Solar urticaria treated with intravenous immunoglobulins" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2010.05.040" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2011" "volumen" => "65" "paginaInicial" => "336" "paginaFinal" => "340" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasmapheresis for severe, unremitting, chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "1992" "volumen" => "339" "paginaInicial" => "1078" "paginaFinal" => "1080" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-IgE (omalizumab) in the treatment of allergic rhinitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Alergol inmunol Clin" "fecha" => "2004" "volumen" => "19" "paginaInicial" => "133" "paginaFinal" => "139" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of chronic autoimmune urticaria with omalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2008.07.006" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2008" "volumen" => "122" "paginaInicial" => "569" "paginaFinal" => "573" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Allergy" "fecha" => "1991" "volumen" => "21" "paginaInicial" => "695" "paginaFinal" => "704" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2008" "volumen" => "121" "paginaInicial" => "S147" ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2010.05.047" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2010" "volumen" => "126" "paginaInicial" => "665" "paginaFinal" => "666" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of omalizumab on patients with chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1081-1206(10)60644-8" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2007" "volumen" => "99" "paginaInicial" => "190" "paginaFinal" => "193" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2011.04.038" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2011" "volumen" => "128" "paginaInicial" => "202" "paginaFinal" => "209" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2007.01591.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "247" "paginaFinal" => "249" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of solar urticaria with anti-immunoglobulin E therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2008.01879.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "1563" "paginaFinal" => "1565" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Partial improvement of solar urticaria after omalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2009.11.007" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2010" "volumen" => "125" "paginaInicial" => "490" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effective treatment of refractory severe heat urticaria with omalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2009.02268.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2010" "volumen" => "65" "paginaInicial" => "931" "paginaFinal" => "932" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of omalizumab in delayed pressure urticaria: a case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2009.02188.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2010" "volumen" => "65" "paginaInicial" => "138" "paginaFinal" => "139" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0315" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of omalizumab in cholinergic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2009" "volumen" => "35" "paginaInicial" => "127" "paginaFinal" => "129" ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0320" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2011.06.010" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2011" "volumen" => "128" "paginaInicial" => "567" "paginaFinal" => "573" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0325" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "1989" "volumen" => "83" "paginaInicial" => "756" "paginaFinal" => "763" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0330" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2005.12.1343" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2006" "volumen" => "117" "paginaInicial" => "1113" "paginaFinal" => "1117" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0335" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2006.08.043" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2007" "volumen" => "119" "paginaInicial" => "705" "paginaFinal" => "710" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0340" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe chronic urticaria is associated with elevated plasma levels of D-dimer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2007.01514.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "176" "paginaFinal" => "180" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0345" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2009.02222.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2010" "volumen" => "65" "paginaInicial" => "649" "paginaFinal" => "656" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0350" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated D-Dimer: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000292947" "Revista" => array:6 [ "tituloSerie" => "Int Arch Allergy Immunol" "fecha" => "2010" "volumen" => "152" "paginaInicial" => "384" "paginaFinal" => "389" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0355" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urticaria treated with dapsone" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "1999" "volumen" => "54" "paginaInicial" => "765" "paginaFinal" => "766" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0360" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2004" "volumen" => "31" "paginaInicial" => "2429" "paginaFinal" => "2432" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0365" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Colchicine in dermatology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1998" "volumen" => "39" "paginaInicial" => "993" "paginaFinal" => "999" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0370" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Microtubule disruption suppresses allergic response through the inhibition of calcium influx in the mast cell degranulation pathway" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Immunol" "fecha" => "2005" "volumen" => "174" "paginaInicial" => "4584" "paginaFinal" => "4589" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0375" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2000" "volumen" => "81" "paginaInicial" => "71" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0380" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "1984" "volumen" => "73" "paginaInicial" => "600" "paginaFinal" => "603" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010500000005/v1_201405281018/S1578219014001127/v1_201405281018/en/main.assets" "Apartado" => array:4 [ "identificador" => "6177" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010500000005/v1_201405281018/S1578219014001127/v1_201405281018/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014001127?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 15 | 20 | 35 |
2024 Octubre | 254 | 65 | 319 |
2024 Septiembre | 260 | 54 | 314 |
2024 Agosto | 264 | 90 | 354 |
2024 Julio | 246 | 43 | 289 |
2024 Junio | 263 | 52 | 315 |
2024 Mayo | 261 | 49 | 310 |
2024 Abril | 185 | 33 | 218 |
2024 Marzo | 248 | 61 | 309 |
2024 Febrero | 366 | 45 | 411 |
2024 Enero | 374 | 62 | 436 |
2023 Diciembre | 348 | 44 | 392 |
2023 Noviembre | 373 | 51 | 424 |
2023 Octubre | 342 | 59 | 401 |
2023 Septiembre | 323 | 43 | 366 |
2023 Agosto | 191 | 35 | 226 |
2023 Julio | 168 | 51 | 219 |
2023 Junio | 181 | 44 | 225 |
2023 Mayo | 183 | 41 | 224 |
2023 Abril | 110 | 28 | 138 |
2023 Marzo | 160 | 47 | 207 |
2023 Febrero | 178 | 31 | 209 |
2023 Enero | 137 | 31 | 168 |
2022 Diciembre | 112 | 42 | 154 |
2022 Noviembre | 76 | 30 | 106 |
2022 Octubre | 68 | 31 | 99 |
2022 Septiembre | 52 | 44 | 96 |
2022 Agosto | 63 | 55 | 118 |
2022 Julio | 48 | 50 | 98 |
2022 Junio | 86 | 51 | 137 |
2022 Mayo | 181 | 55 | 236 |
2022 Abril | 230 | 47 | 277 |
2022 Marzo | 186 | 66 | 252 |
2022 Febrero | 232 | 36 | 268 |
2022 Enero | 185 | 60 | 245 |
2021 Diciembre | 117 | 68 | 185 |
2021 Noviembre | 117 | 71 | 188 |
2021 Octubre | 120 | 71 | 191 |
2021 Septiembre | 133 | 56 | 189 |
2021 Agosto | 109 | 51 | 160 |
2021 Julio | 97 | 34 | 131 |
2021 Junio | 123 | 51 | 174 |
2021 Mayo | 131 | 50 | 181 |
2021 Abril | 722 | 73 | 795 |
2021 Marzo | 308 | 20 | 328 |
2021 Febrero | 168 | 46 | 214 |
2021 Enero | 112 | 36 | 148 |
2020 Diciembre | 141 | 28 | 169 |
2020 Noviembre | 73 | 18 | 91 |
2020 Octubre | 67 | 18 | 85 |
2020 Septiembre | 80 | 17 | 97 |
2020 Agosto | 76 | 16 | 92 |
2020 Julio | 73 | 22 | 95 |
2020 Junio | 74 | 16 | 90 |
2020 Mayo | 70 | 12 | 82 |
2020 Abril | 51 | 16 | 67 |
2020 Marzo | 41 | 8 | 49 |
2020 Febrero | 10 | 2 | 12 |
2020 Enero | 4 | 0 | 4 |
2019 Diciembre | 8 | 2 | 10 |
2019 Noviembre | 4 | 2 | 6 |
2019 Octubre | 0 | 1 | 1 |
2019 Septiembre | 10 | 2 | 12 |
2019 Agosto | 5 | 0 | 5 |
2019 Julio | 3 | 7 | 10 |
2019 Junio | 15 | 6 | 21 |
2019 Mayo | 1 | 18 | 19 |
2019 Abril | 12 | 1 | 13 |
2019 Marzo | 3 | 6 | 9 |
2019 Febrero | 2 | 0 | 2 |
2019 Enero | 7 | 0 | 7 |
2018 Diciembre | 3 | 0 | 3 |
2018 Noviembre | 6 | 0 | 6 |
2018 Octubre | 3 | 0 | 3 |
2018 Septiembre | 3 | 0 | 3 |
2018 Junio | 0 | 4 | 4 |
2018 Mayo | 0 | 2 | 2 |
2018 Abril | 0 | 12 | 12 |
2018 Marzo | 2 | 7 | 9 |
2018 Febrero | 108 | 10 | 118 |
2018 Enero | 80 | 23 | 103 |
2017 Diciembre | 78 | 13 | 91 |
2017 Noviembre | 81 | 17 | 98 |
2017 Octubre | 73 | 10 | 83 |
2017 Septiembre | 73 | 20 | 93 |
2017 Agosto | 82 | 14 | 96 |
2017 Julio | 68 | 20 | 88 |
2017 Junio | 80 | 10 | 90 |
2017 Mayo | 85 | 34 | 119 |
2017 Abril | 64 | 14 | 78 |
2017 Marzo | 78 | 29 | 107 |
2017 Febrero | 65 | 18 | 83 |
2017 Enero | 61 | 20 | 81 |
2016 Diciembre | 102 | 20 | 122 |
2016 Noviembre | 170 | 26 | 196 |
2016 Octubre | 176 | 21 | 197 |
2016 Septiembre | 233 | 16 | 249 |
2016 Agosto | 212 | 24 | 236 |
2016 Julio | 79 | 13 | 92 |
2016 Junio | 7 | 18 | 25 |
2016 Mayo | 4 | 1 | 5 |
2016 Abril | 5 | 5 | 10 |
2016 Marzo | 7 | 4 | 11 |
2016 Febrero | 9 | 5 | 14 |
2016 Enero | 6 | 4 | 10 |
2015 Diciembre | 5 | 4 | 9 |
2015 Noviembre | 3 | 7 | 10 |
2015 Octubre | 6 | 24 | 30 |
2015 Septiembre | 2 | 11 | 13 |
2015 Agosto | 10 | 2 | 12 |
2015 Julio | 163 | 15 | 178 |
2015 Junio | 89 | 19 | 108 |
2015 Mayo | 98 | 27 | 125 |
2015 Abril | 74 | 11 | 85 |
2015 Marzo | 83 | 9 | 92 |
2015 Febrero | 85 | 5 | 90 |
2015 Enero | 68 | 9 | 77 |
2014 Diciembre | 58 | 9 | 67 |
2014 Noviembre | 78 | 15 | 93 |
2014 Octubre | 59 | 10 | 69 |
2014 Septiembre | 62 | 10 | 72 |
2014 Agosto | 55 | 10 | 65 |
2014 Julio | 30 | 21 | 51 |
2014 Junio | 23 | 10 | 33 |
2014 Mayo | 3 | 1 | 4 |